New combo therapy hopes to tackle tough lymphoma
NCT ID NCT03533283
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 211 participants will receive the drugs intravenously over several cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glofitamab, atezolizumab, polatuzumab vedotin, obinutuzumab
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat B-cell non-Hodgkin lymphoma, potentially improving response rates.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so results may not apply broadly. Side effects from the drug combinations could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKINS LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus Universitetshospital Skejby
Aarhus N, 8200, Denmark
-
Asst Papa Giovanni Xxiii
Bergamo, Lombardy, 24127, Italy
-
Chaim Sheba Medical Center
Ramat Gan, 52621, Israel
-
Fond. IRCCS Istituto Nazionale Tumori
Milan, Lombardy, 20133, Italy
-
Hadassah Ein Karem Hospital
Jerusalem, 9112001, Israel
-
Hospital Clinico Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Duran i Reynals
Barcelona, 08907, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Istituto Nazionale Tumori Irccs Fondazione g. Pascale
Naples, Campania, 80131, Italy
-
Odense Universitetshospital
Odense C, 5000, Denmark
-
Policlinico S.Orsola-Malpighi
Bologna, Emilia-Romagna, 40138, Italy
-
Rabin Medical Center-Beilinson Campus
Petah Tikva, 4941492, Israel
-
Rigshospitalet
København Ø, 2100, Denmark
-
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
The HOPE Clinical Trials Unit
Leicester, LE1 5WW, United Kingdom
-
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
UZ Gent
Ghent, 9000, Belgium
-
University College London Hospitals NHS Foundation Trust
London, W1T 7HA, United Kingdom